CR20120491A - Proteinas de unión a antigeno especificas para el componente amiloide serico p - Google Patents
Proteinas de unión a antigeno especificas para el componente amiloide serico pInfo
- Publication number
- CR20120491A CR20120491A CR20120491A CR20120491A CR20120491A CR 20120491 A CR20120491 A CR 20120491A CR 20120491 A CR20120491 A CR 20120491A CR 20120491 A CR20120491 A CR 20120491A CR 20120491 A CR20120491 A CR 20120491A
- Authority
- CR
- Costa Rica
- Prior art keywords
- binding proteins
- antigen
- component
- serico
- amiloid
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 5
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30995710P | 2010-03-03 | 2010-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120491A true CR20120491A (es) | 2013-02-20 |
Family
ID=43881068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120491A CR20120491A (es) | 2010-03-03 | 2012-09-27 | Proteinas de unión a antigeno especificas para el componente amiloide serico p |
Country Status (39)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012012887A2 (pt) * | 2009-12-02 | 2017-05-02 | Imaginab Inc | minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito. |
| CN105188749B (zh) * | 2012-12-21 | 2017-12-19 | 西雅图基因公司 | 抗ntb‑a抗体及相关组合物和方法 |
| CN103239713A (zh) * | 2013-05-28 | 2013-08-14 | 东南大学 | 一种糖尿病肾病微炎症小鼠模型的建立方法 |
| US9737505B2 (en) * | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201407506D0 (en) | 2014-04-29 | 2014-06-11 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| MX2018001566A (es) | 2015-08-07 | 2019-04-25 | Imaginab Inc | Construcciones de union a antigeno para moleculas diana. |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| WO2019185502A1 (en) | 2018-03-26 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Antibodies comprising methionine sulfoxide at the ch2-ch3 interface |
| CN116925216B (zh) * | 2022-04-11 | 2024-09-24 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| GB9317120D0 (en) * | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| IL131131A0 (en) | 1997-02-07 | 2001-01-28 | Merck & Co Inc | Synthetic hiv gag genes |
| DE69808017T2 (de) * | 1997-10-31 | 2003-04-30 | F. Hoffmann-La Roche Ag, Basel | D-Prolinderivate |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| US6903129B2 (en) | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| AU2003299873A1 (en) | 2002-12-23 | 2004-07-22 | Univ Rice William M | Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| US7553819B2 (en) | 2003-05-12 | 2009-06-30 | Theracarb Inc. | Multivalent inhibitors of serum amyloid P component |
| CA2573745A1 (en) | 2004-07-21 | 2007-01-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| AU2008358292B2 (en) * | 2008-06-27 | 2015-05-07 | Pentraxin Therapeutics Limited | Use |
-
2011
- 2011-01-03 UA UAA201210015A patent/UA108227C2/uk unknown
- 2011-03-01 RS RS20181162A patent/RS57708B1/sr unknown
- 2011-03-01 LT LTEP15178026.9T patent/LT3025729T/lt unknown
- 2011-03-01 NZ NZ601763A patent/NZ601763A/en not_active IP Right Cessation
- 2011-03-01 SI SI201130964A patent/SI2542261T1/sl unknown
- 2011-03-01 PH PH1/2012/501743A patent/PH12012501743A1/en unknown
- 2011-03-01 DK DK15178026.9T patent/DK3025729T3/en active
- 2011-03-01 PT PT117056176T patent/PT2542261T/pt unknown
- 2011-03-01 PE PE2012001385A patent/PE20130040A1/es not_active Application Discontinuation
- 2011-03-01 PL PL11705617.6T patent/PL2542261T3/pl unknown
- 2011-03-01 MY MYPI2012003903A patent/MY159255A/en unknown
- 2011-03-01 EP EP15178026.9A patent/EP3025729B1/en active Active
- 2011-03-01 DK DK11705617.6T patent/DK2542261T3/en active
- 2011-03-01 CN CN201180017717.1A patent/CN102858371B/zh not_active Expired - Fee Related
- 2011-03-01 JO JOP/2011/0075A patent/JO3188B1/ar active
- 2011-03-01 ES ES11705617.6T patent/ES2593454T3/es active Active
- 2011-03-01 TW TW100106740A patent/TWI558409B/zh not_active IP Right Cessation
- 2011-03-01 MA MA35252A patent/MA34135B1/fr unknown
- 2011-03-01 SI SI201131594T patent/SI3025729T1/sl unknown
- 2011-03-01 AR ARP110100618A patent/AR080432A1/es not_active Application Discontinuation
- 2011-03-01 EP EP11705617.6A patent/EP2542261B1/en active Active
- 2011-03-01 MX MX2012010129A patent/MX340350B/es active IP Right Grant
- 2011-03-01 PT PT15178026T patent/PT3025729T/pt unknown
- 2011-03-01 CA CA2789557A patent/CA2789557A1/en not_active Abandoned
- 2011-03-01 ME MEP-2016-161A patent/ME02491B/me unknown
- 2011-03-01 WO PCT/EP2011/053038 patent/WO2011107480A1/en not_active Ceased
- 2011-03-01 ES ES15178026T patent/ES2699078T3/es active Active
- 2011-03-01 KR KR1020127025884A patent/KR101817265B1/ko not_active Expired - Fee Related
- 2011-03-01 AU AU2011223048A patent/AU2011223048C1/en not_active Ceased
- 2011-03-01 SM SM20180633T patent/SMT201800633T1/it unknown
- 2011-03-01 HR HRP20161096TT patent/HRP20161096T1/hr unknown
- 2011-03-01 RS RS20160741A patent/RS55133B1/sr unknown
- 2011-03-01 LT LTEP11705617.6T patent/LT2542261T/lt unknown
- 2011-03-01 SG SG2012060216A patent/SG183316A1/en unknown
- 2011-03-01 BR BR112012021926-0A patent/BR112012021926A2/pt not_active IP Right Cessation
- 2011-03-01 PL PL15178026T patent/PL3025729T3/pl unknown
- 2011-03-01 SG SG10201500382SA patent/SG10201500382SA/en unknown
- 2011-03-01 EA EA201290671A patent/EA026375B1/ru not_active IP Right Cessation
- 2011-03-01 JP JP2012555403A patent/JP5922592B2/ja not_active Expired - Fee Related
- 2011-03-01 HU HUE11705617A patent/HUE028960T2/en unknown
- 2011-03-03 UY UY0001033258A patent/UY33258A/es not_active Application Discontinuation
-
2012
- 2012-08-12 IL IL221418A patent/IL221418A/en not_active IP Right Cessation
- 2012-08-22 DO DO2012000232A patent/DOP2012000232A/es unknown
- 2012-08-30 ZA ZA2012/06529A patent/ZA201206529B/en unknown
- 2012-08-31 CO CO12149377A patent/CO6602134A2/es unknown
- 2012-08-31 CL CL2012002418A patent/CL2012002418A1/es unknown
- 2012-09-27 CR CR20120491A patent/CR20120491A/es unknown
-
2016
- 2016-02-05 JP JP2016020718A patent/JP6236478B2/ja not_active Expired - Fee Related
- 2016-09-23 CY CY20161100950T patent/CY1118046T1/el unknown
- 2016-09-26 SM SM201600337T patent/SMT201600337B/it unknown
-
2017
- 2017-03-08 IL IL251031A patent/IL251031A/en not_active IP Right Cessation
-
2018
- 2018-10-12 HR HRP20181666TT patent/HRP20181666T1/hr unknown
- 2018-10-31 CY CY181101126T patent/CY1120803T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120491A (es) | Proteinas de unión a antigeno especificas para el componente amiloide serico p | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| MX355268B (es) | Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos. | |
| UY32341A (es) | Proteínas de unión antígeno novedosas | |
| AR092779A1 (es) | Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau | |
| CL2015001314A1 (es) | Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14). | |
| ECSP13012609A (es) | Composición farmacéutica | |
| CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
| UY33421A (es) | Proteinas de union al antígeno humanizados | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| CL2013002888A1 (es) | Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011). | |
| MX2019012445A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| PE20100684A1 (es) | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh | |
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
| AR076655A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| MX374708B (es) | Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos. | |
| CL2008003197A1 (es) | Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer. | |
| CO7240362A2 (es) | Molécula de unión il-6 | |
| BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
| BR112015004119A2 (pt) | anticorpos monoclonais para melhorar ou inibir o fator de crescimento semelhante à insulina tipo 1 (igf-1) | |
| BR112013023211A2 (pt) | ensaio diagnóstico de anticorpos | |
| BR112013005423A2 (pt) | composições de anticorpo anti-vegfr-3. | |
| UY36098A (es) | Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica. | |
| AR124605A2 (es) | Anticuerpos anti-il-36r | |
| BR112014027372A2 (pt) | anticorpos anti-il-23p19 |